GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » Tax Expense

CardioGenics Holdings (CardioGenics Holdings) Tax Expense : $0.00 Mil (TTM As of Jan. 2016)


View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings Tax Expense?

CardioGenics Holdings's tax expense for the months ended in Jan. 2016 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jan. 2016 was $0.00 Mil.


CardioGenics Holdings Tax Expense Historical Data

The historical data trend for CardioGenics Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings Tax Expense Chart

CardioGenics Holdings Annual Data
Trend Jul06 Jul07 Jul08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CardioGenics Holdings Quarterly Data
Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Jul15 Oct15 Jan16
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CardioGenics Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jan. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CardioGenics Holdings  (OTCPK:CGNH) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


CardioGenics Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


CardioGenics Holdings (CardioGenics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8
CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines